Jennifer J Gao
14PUBLICATIONS
56CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (14)
Sort by Publication Date:
|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.Jennifer J Gao, Tatiana M Prowell, Haley Gittleman
|Oct 08, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.Sundeep Agrawal, Clara Lee, William F Pierce
|Jun 10, 2024
Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship.Timil Patel, Chris Chen, Samer Al Hadidi
|Aug 18, 2023
FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.Jennifer J Gao, Christy L Osgood, Zhou Feng
|Oct 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.Shaily Arora, Preeti Narayan, Christy L Osgood
|Oct 29, 2021
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.Shaily Arora, Preeti Narayan, Gwynn Ison
Pageof 3
Frequent Collaborators
6 joint publications
Richard Pazdur
5 joint publications
Tatiana M Prowell
4 joint publications
Laleh Amiri-Kordestani
3 joint publications
Shenghui Tang
3 joint publications
Melanie Royce
3 joint publications
William F Pierce
3 joint publications
Paul Kluetz
2 joint publications
Christy L Osgood
2 joint publications
Amna Ibrahim
2 joint publications
Kirsten B Goldberg
